Reneo Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands, except share data)
| Additional · AccumulatedOther · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders’ | ||||||||
| Shares · Amount · Capital · Income (Loss) · Deficit · Equity | ||||||||
| Balances, December 31, 2021 | 24,455,390 | $3 | $231,902 | $34 | $(84,728) | $147,211 | ||
| Stock based compensation | — | — | 4,320 | — | — | 4,320 | ||
| Issuance of common stock in connection with at-the-market facility, net of issuance costs | 92,085 | — | 193 | — | — | 193 | ||
| Issuance of common stock in connection with equity plans | 152,078 | — | 278 | — | — | 278 | ||
| Other comprehensive loss | — | — | — | (77) | — | (77) | ||
| Net loss | — | — | — | — | (51,955) | (51,955) | ||
| Balances, December 31, 2022 | 24,699,553 | $3 | $236,693 | $(43) | $(136,683) | $99,970 | ||
| Stock based compensation | — | — | 5,112 | — | — | 5,112 | ||
| Issuance of common stock in public offering, net of offering costs | 7,906,250 | — | 58,862 | — | — | 58,862 | ||
| Issuance of common stock in private placement, net of offering costs | 625,000 | — | 4,667 | 4,667 | ||||
| Issuance of common stock in connection with at-the-market facility, net of issuance costs | 407,877 | — | 1,009 | — | — | 1,009 | ||
| Issuance of common stock in connection with equity plans | 358,571 | — | 730 | — | — | 730 | ||
| Repurchase and retirement of common stock in connection with common stock repurchase agreement | (576,443) | — | — | — | (4,403) | (4,403) | ||
| Other comprehensive income | — | — | — | 51 | 51 | |||
| Net loss | — | — | — | — | (77,388) | (77,388) | ||
| Balances, December 31, 2023 | 33,420,808 | $3 | $307,073 | $8 | $(218,474) | $88,610 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.